NZCR is at the forefront of early phase clinical research. Our focus on quality and innovation has resulted in many exciting medical breakthroughs. These news articles highlight current research projects and innovations at NZCR.
Home / About Us / About NZCR / News
NZCR was recently involved in promising Phase-1 research of a new drug, TLC-2716, to treat people with severe high triglycerides and NASH. These promising early results, enables OrsoBio to move on to Phase-2a stage of testing with patients who have high triglycerides and liver fat.
Clinical trials are an incredibly important part of the process to bring new drugs to market and a participant’s safety is the number one priority in any clinical study. Read about the safety protocols and checks completed throughout the trial process.
Before any new drug or medicine can be bought to market, the Sponsor or Developer must prove the drug does what it is intended to do, all side effects are known and understood, and it is safe for humans to take. This article outlines the clinical research processes and checks NZCR must follow to ensure trials are conducted safely and ethically.
New Zealand Clinical Research (NZCR) undertakes clinical trials in NZ for many medical and pharmaceutical groups around the world. This must be done under strict regulatory controls to ensure the medical trial is conducted safely, ethically, and with scientific rigour. Learn about the meticulous review process NZCR must undergo before they can start trialing any new drug.
Many medical trial participants prefer participating in a biosimilar study because the medication has already been tested and approved. Biosimilar studies test new variants of an already approved drug and aim to prove that a newly created version is the same as an existing one.
They say “good things take time”, and never has that been more true than in the case of Trikafta, a new treatment for the symptoms of Cystic Fibrosis, now funded by Pharmac.
There is evidence that different ethnic groups may respond differently to certain treatments due to genetic and environmental factors. A lack of diversity in clinical trials in NZ can perpetuate health disparities and limit access to treatments for underrepresented groups.
New Zealand Clinical Research (NZCR) is a leading early-phase clinical research provider. Our expert research team has conducted over 750 clinical studies in NZ involving more than 15,000 New Zealanders. With facilities in Wellington, Hamilton, Christchurch, and Auckland, clinical trials are being conducted daily to test investigative medicines. For NZCR to do this research it needs healthy people and patients to join its research community.
NZCR, a top provider of clinical trials in NZ, was commissioned to run the world’s first ‘in-human’ trial of this Nobel prize winning technique.
NZCR's Professor Ed Gane is a world leading researcher. His recent research of Hepatitis B in Japanese and Non Japanese subjects has recently been published in Anti Viral Therapy
The life of a participant in clinical trials in NZ gives individuals the opportunity to take part in research that could improve many people's lives. Participating in a clinical trial in NZ can vary depending on the type of trial and its objectives, and medical trials can be from one day to up to 18 days with follow-up visits.
Clinical trials in NZ are designed to advance global health, and usually are part of a multi-country trial approach. At NZCR , our clinical research teams’ partner with leading medical researchers, doctors and science experts to help develop innovative medicines and treatments that improve people's lives.
New Zealand Clinical Research (NZCR) provides state of the art research facilities and the expertise to conduct complex early phase clinical research in healthy participant and patient populations.